» Articles » PMID: 34823536

Effect of Blood Lipid Variability on Mortality in Patients with Type 2 Diabetes: a Large Single-center Cohort Study

Overview
Publisher Biomed Central
Date 2021 Nov 26
PMID 34823536
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dyslipidemia is a major cardiovascular risk factor and common in diabetes patients. Most guidelines focus on optimal lipid levels, while variation of lipid profiles is far less discussed. This study aims to investigate the association of visit-to-visit variability in blood lipids with all-cause, cardiovascular, and non-cardiovascular mortality in patients with type 2 diabetes.

Methods: We identified 10,583 type 2 diabetes patients aged ≥ 30 years with follow-up ≥ 3 years and who participated in the Diabetes Care Management Program at a medical center in Taiwan. Variability in lipid profiles within 3 years after entry was calculated using coefficient of variation. Cox proportional hazard models were used to evaluate lipid variability in relation to subsequent mortality.

Results: Over a mean follow-up of 6.4 years, 1838 all-cause deaths (809 cardiovascular deaths) were observed. For each 10% increase in variability in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total cholesterol, the hazard ratios (95% confidence intervals) of all-cause mortality were 1.30 (1.22-1.37), 1.05 (1.01-1.09), and 1.10 (1.03-1.16), respectively; those of cardiovascular mortality were 1.27 (1.16-1.39), 1.08 (1.02-1.15), and 1.16 (1.07-1.27), respectively. Each 10% increase in high-density lipoprotein cholesterol variability conveyed 31% greater risk of non-cardiovascular mortality. High variability in total cholesterol and low-density lipoprotein cholesterol increased all-cause mortality in subgroups of nonsmoking, regular exercising, non-dyslipidemia, and more severe status of diabetes at baseline.

Conclusions: Blood lipid variability except for triglyceride variability was associated with all-cause and cardiovascular mortality in patients with type 2 diabetes.

Citing Articles

Untargeted Lipidomic Reveals Potential Biomarkers in Plasma Samples for the Discrimination of Patients Affected by Parkinson's Disease.

Tkachenko K, Gonzalez-Saiz J, Pizarro C Molecules. 2025; 30(4).

PMID: 40005161 PMC: 11857942. DOI: 10.3390/molecules30040850.


High-Density Lipoprotein in Patients with Diabetic Kidney Disease: Friend or Foe?.

Liu K, Cooper M, Chai Z, Liu F Int J Mol Sci. 2025; 26(4).

PMID: 40004147 PMC: 11855193. DOI: 10.3390/ijms26041683.


Visit-to-visit lipid variability on long-term major adverse cardiovascular events: a prospective multicentre cohort from the CORE-Thailand registry.

Teekaput C, Thiankhaw K, Wongcharoen W, Prasertwitayakij N, Gunaparn S, Phrommintikul A Sci Rep. 2025; 15(1):1953.

PMID: 39809804 PMC: 11733244. DOI: 10.1038/s41598-025-85453-w.


Analyzivng Demand for Customized Obesity Prevention and Management Across Adult Age Groups Using Focus Group Interview.

Park J, Park S, Kim M Inquiry. 2024; 61:469580241271152.

PMID: 39183602 PMC: 11348362. DOI: 10.1177/00469580241271152.


Association between serum lipid and all-cause mortality in asthmatic populations: a cohort study.

Wen J, Zhuang R, He Q, Wei C, Giri M, Chi J Lipids Health Dis. 2024; 23(1):189.

PMID: 38907251 PMC: 11191228. DOI: 10.1186/s12944-024-02179-w.


References
1.
Bowe B, Xie Y, Xian H, Balasubramanian S, Zayed M, Al-Aly Z . High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clin J Am Soc Nephrol. 2016; 11(10):1784-1793. PMC: 5053782. DOI: 10.2215/CJN.00730116. View

2.
Lin Y, Huang J, Wu P, Chen S, Chiu Y, Chang J . Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3. Oncotarget. 2018; 9(3):3242-3253. PMC: 5790460. DOI: 10.18632/oncotarget.23228. View

3.
Chiriaco M, Pateras K, Virdis A, Charakida M, Kyriakopoulou D, Nannipieri M . Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2019; 21(12):2587-2598. DOI: 10.1111/dom.13828. View

4.
Clark 3rd D, Puri R, Nissen S . Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients. Expert Rev Cardiovasc Ther. 2020; 18(12):873-880. DOI: 10.1080/14779072.2020.1833716. View

5.
Hsu W, Lai C, Chen S, Chiou H, Hsiao P, Shin S . GREATER LOW-DENSITY LIPOPROTEIN CHOLESTEROL VARIABILITY INCREASES THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Endocr Pract. 2019; 25(9):918-925. DOI: 10.4158/EP-2019-0002. View